Literature DB >> 11950398

Prognostic significance of amino acid transport imaging in patients with brain tumors.

Matthias Weckesser1, Peter Matheja, Antje Schwarzrock, Christian H Rickert, Ronald Sträter, Stefan Palkovic, Burkhard Riemann, Klaus Kopka, Peter Lüdemann, Werner Paulus, Hansdetlef Wassmann, Otmar Schober.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of presence, intensity, and extent of amino acid uptake in patients with suspected primary or recurrent brain tumors.
METHODS: We retrospectively analyzed 181 consecutive studies of amino acid uptake using single-photon emission computed tomography and the amino acid l-[3-(123)I]iodo-alpha-methyltyrosine (IMT). In a blinded analysis, all studies were evaluated for presence, maximal uptake (IMT(max)), and extent (IMT(ext)) of focal tracer uptake.
RESULTS: The most frequent tumors were 53 astrocytomas (World Health Organization Grade I-III), 41 glioblastomas, 16 metastases, 13 oligodendrogliomas (Grade II-III), and 10 medulloblastomas. The other patients exhibited various parenchymal tumors or nonneoplastic lesions. IMT uptake was present in 69% of the patients with IMT(max) ranging from 1.4 to 6.2. IMT(max) and IMT(ext) were significant predictors of survival in the whole group. When the group was divided according to primary versus recurrent tumor, only the primary tumors achieved a high level of significance (P < 0.01). When patients without any IMT uptake were excluded from the analysis, statistical significance for both IMT(max) and IMT(ext) was lost. Multiple regression analysis, including IMT(max), IMT(ext), age, and tumor grade, revealed only extent of IMT uptake as an independent predictor of prognosis.
CONCLUSION: Absence of IMT uptake is a significant predictor of long-term survival in patients with suspected primary or recurrent brain tumors. Only the extent of a given lesion provided minor supplementary prognostic information as compared with histopathology and age. These findings suggest caution in relating high amino acid uptake values to poor prognosis, despite the capability of amino acid imaging to help determine the presence and extent of gliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950398     DOI: 10.1097/00006123-200205000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

1.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

2.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.

Authors:  S Ceyssens; K Van Laere; T de Groot; J Goffin; G Bormans; L Mortelmans
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

3.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Authors:  Koen Van Laere; Sarah Ceyssens; Frank Van Calenbergh; Tjibbe de Groot; Johan Menten; Patrick Flamen; Guy Bormans; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.